Articles by master

Saiba AG focuses on a future COVID-19 vaccine with advantages over first to market vaccine candidates

Saiba AG has decided to focus on optimization of its vaccine candidate rather than rush into clinical studies in 2020.

Read More

Allergy Therapeutics secures virus-like particle (“VLP”) technology platform to broaden vaccine pipeline through licensing agreements with Saiba AG and DeepVax GmbH

Group to investigate potential of VLP technology in oncology and other immune conditions after encouraging proof of concept findings Builds on positive ongoing progress in VLP-based peanut allergy candidate vaccine VLP platform to be combined with Allergy Therapeutics’ proprietary adjuvant technology Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy …

Read More

Saiba AG Selects AGC Biologics to Develop and Produce COVID-19 Vaccine

Saiba proprietary technology has enabled scientists to generate a vaccine candidate against COVID-19 with preclinical proof-of-concept.

Read More

Saiba AG Shows encouraging preclinical data for its COVID-19 VLP-based vaccine

(PFÄFFIKON), March 25, 2020 — Saiba AG, https://www.saiba-biotech.com/ , has developed a proprietary platform technology based on immunologically optimized virus-like particles. This platform technology has now enabled scientists to establish preclinical proof-of-concept for a vaccine against COVID-19. The vaccine candidate has been able to induce in test animals high levels of antibodies that neutralize the …

Read More